07.09.2016 – Furniture giant Ikea and renewables expert Neste have joined forces to deliver bio-based plastics based on Neste’s bio-based polymer. The partners urge other companies to join the initiative.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160907-ikea-neste.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-09-07 00:00:002016-09-07 00:00:00Bed and board go bio-based
Matthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September.
06.09.2016 – DBV’s needle-free patch technology is being put to the test in a a proof of concept trial for a pertussis vaccine developed by BioNet-Asia. Researchers from the Geneva University Hospital are supervising the study.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160906-needlefree-vaccine.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-09-06 00:00:002016-09-06 00:00:00Boosting vaccines without the prick
05.09.2016 – Why do people grow old? Italian researchers took a close look at centenarians and found that low levels of the peptide hormone Adrenomedullin may significantly contribute towards good microcirculation and thus longevity.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160905-acciaroli.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-09-05 00:00:002016-09-05 00:00:00Biomarker lifts a secret of old age
Swedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, which was acquired by Johnson & Johnson last December.
01.09.2016 – The causes of Alzheimer’s disease are still largely unknown. But now, an antibody developed by the University of Zurich has significantly reduced the brain amyloid plaques typical for Alzheimer’s Disease in a Phase Ib clinical trial.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160901-alzheimer.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-09-01 00:00:002016-09-01 00:00:00mAb ray of hope for Alzheimer’s
30.08.2016 – Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160830-herniated-disc.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-08-30 00:00:002016-08-30 00:00:00Ferring bags slipped disk pain drug
Brussels-based vaccine developer Univac has appointed a new CEO. In March, Stefano Malvolti joined Univac from Gavi, the Vaccine Alliance, where he was responsible for rolling out the vaccine development programmes of the public-private partnership.
https://european-biotechnology.com/wp-content/uploads/2024/04/stefano-malvolti.jpg322286h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-08-29 00:00:002016-08-29 00:00:00Vaccine pro
Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160826-adocia.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-08-26 00:00:002016-08-26 00:00:00Phase III washout for Adocia
24.08.2016 – Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
Bed and board go bio-based
Latest News07.09.2016 – Furniture giant Ikea and renewables expert Neste have joined forces to deliver bio-based plastics based on Neste’s bio-based polymer. The partners urge other companies to join the initiative.
Immunotherapy pioneer
AppointmentsMatthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September.
Boosting vaccines without the prick
Latest News06.09.2016 – DBV’s needle-free patch technology is being put to the test in a a proof of concept trial for a pertussis vaccine developed by BioNet-Asia. Researchers from the Geneva University Hospital are supervising the study.
Biomarker lifts a secret of old age
Latest News05.09.2016 – Why do people grow old? Italian researchers took a close look at centenarians and found that low levels of the peptide hormone Adrenomedullin may significantly contribute towards good microcirculation and thus longevity.
Overseas chief
AppointmentsSwedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, which was acquired by Johnson & Johnson last December.
mAb ray of hope for Alzheimer’s
Latest News01.09.2016 – The causes of Alzheimer’s disease are still largely unknown. But now, an antibody developed by the University of Zurich has significantly reduced the brain amyloid plaques typical for Alzheimer’s Disease in a Phase Ib clinical trial.
Ferring bags slipped disk pain drug
Latest News30.08.2016 – Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.
Vaccine pro
AppointmentsBrussels-based vaccine developer Univac has appointed a new CEO. In March, Stefano Malvolti joined Univac from Gavi, the Vaccine Alliance, where he was responsible for rolling out the vaccine development programmes of the public-private partnership.
Phase III washout for Adocia
Latest NewsAdocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
AZ unloads antibiotics to Pfizer
Latest News24.08.2016 – Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.